Lyell Immunopharma (LYEL) Cash & Equivalents (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Cash & Equivalents data on file, last reported at $90.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 24.56% year-over-year to $90.8 million; the trailing twelve-month figure through Mar 2026 stood at $90.8 million (down 24.56% YoY), and the FY2025 full-year result was $60.2 million, down 43.01% from the prior year.
• Cash & Equivalents climbed to $90.8 million in Q1 2026, from $60.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $286.2 million in Q3 2023 to a low of $60.2 million in Q4 2025.
• A 5-year average of $140.7 million and a median of $123.6 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 70.44% in 2022 and jumped 146.08% in 2023, its largest moves.
• Tracing LYEL's Cash & Equivalents over 5 years: stood at $123.6 million in 2022, then climbed by 17.88% to $145.6 million in 2023, then retreated by 27.5% to $105.6 million in 2024, then tumbled by 43.01% to $60.2 million in 2025, then soared by 50.83% to $90.8 million in 2026.
• Business Quant data shows LYEL's Cash & Equivalents at $90.8 million in Q1 2026, $60.2 million in Q4 2025, and $123.6 million in Q3 2025.